Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus
Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection
Strengthened balance sheet with $57.5 million financing to advance transplantation programs
IRVINE, Calif., November 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent business highlights.
“The results from our Phase 2 BESTOW trial demonstrated tegoprubart’s excellent efficacy and safety, importantly avoiding many of the long-term toxicities commonly seen with current standard-of-care immunosuppressive therapies,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “Further, the proceeds from our recent financing enhance our ability to advance tegoprubart’s programs in kidney transplantation, islet cell transplantation, and xenotransplantation, addressing critical unmet needs in transplant medicine.”
Third Quarter 2025 and Business Highlights
•
Presented results from the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting in Houston, TX. Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus. Kidney function, as measured by estimated glomerular filtration rate (eGFR), was approximately 69 mL/min/1.732 at 12-months for participants in the tegoprubart treatment arm (n=51).
•
Based on the Phase 2 BESTOW results, Eledon plans to advance tegoprubart into Phase 3 development following discussions with regulators on study design and data requirements. Insights from the Phase 2 BESTOW data set and the ongoing long-term extension study will be incorporated to optimize the Phase 3 protocol and strengthen the regulatory package.
•
On November 13, 2025, Eledon completed an underwritten public offering of common stock and pre-funded warrants, resulting in total gross proceeds of $57.5 million and net proceeds of approximately $53.6 million after deducting underwriting discounts, commissions, and estimated offering expenses.
Anticipated Upcoming YE2025 and 2026 Milestones
•
4Q 2025: Enroll final three patients with Type 1 diabetes in the investigator-led clinical study at UChicago Medicine evaluating tegoprubart in islet cell transplantation.
•
2026: Receive U.S. Food & Drug Administration (“FDA”) guidance on the Phase 3 trial design for kidney transplantation, and subsequently initiate a Phase 3 trial in kidney transplantation.
•
2026: Report long-term data from the Phase 1 and Phase 2 BESTOW studies in kidney transplantation.
•
2026: Report data from nine patients in the investigator-led islet cell transplantation study.
•
2026: Receive FDA regulatory guidance on path to market for islet cell transplantation & xenotransplantation.
Third Quarter 2025 Financial Results
Cash, cash equivalents and short-term investments totaled $93.4 million as of September 30, 2025 compared to $140.2 million as of December 31, 2024.
Research and development (R&D) expenses for the third quarter of 2025 were $15.0 million, including $1.1 million of non-cash stock-based compensation expense, compared to $16.5 million, including $0.4 million of non-cash stock-based compensation expense, for the comparable period in 2024.
General and administrative expenses for the third quarter of 2025 were $4.1 million, including $1.4 million of non-cash stock-based compensation expense, compared to $4.0 million, including $1.4 million of non-cash stock-based compensation expense, for the comparable period in 2024.
Net loss for the third quarter of 2025 was $17.5 million, or $0.21 per basic common share, compared to a net income of $77.0 million, or $1.05 per basic common share, for the comparable period in 2024. Net income in the third quarter of 2024 included a non-cash gain of $96.4 million related to changes in the fair value of warrant liabilities. Excluding this non-cash gain, Eledon would have recorded a net loss of $19.5 million for the third quarter of 2024.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, liver allograft transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter This press release contains forward-looking statements that involve substantial risks and uncertainties.
Forward Looking Statements
Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Stephen Jasper Gilmartin Group (858) 525 2047 stephen@gilmartinir.com Jenna Urban CG Life (212) 253 8881
Media Contact:
jurban@cglife.com
Source: Eledon Pharmaceuticals
ELEDON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30,
2025 |
|
|
December 31,
2024 |
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
3,669 |
|
|
$ |
20,549 |
|
Short-term investments |
|
|
89,732 |
|
|
|
119,629 |
|
Prepaid expenses and other current assets |
|
|
2,900 |
|
|
|
3,552 |
|
Total current assets |
|
|
96,301 |
|
|
|
143,730 |
|
Operating lease asset, net |
|
|
694 |
|
|
|
926 |
|
In-process research and development |
|
|
32,386 |
|
|
|
32,386 |
|
Other assets |
|
|
476 |
|
|
|
363 |
|
Total assets |
|
$ |
129,857 |
|
|
$ |
177,405 |
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
4,627 |
|
|
$ |
5,833 |
|
Current operating lease liabilities |
|
|
346 |
|
|
|
314 |
|
Accrued expenses and other liabilities |
|
|
9,323 |
|
|
|
5,430 |
|
Total current liabilities |
|
|
14,296 |
|
|
|
11,577 |
|
Deferred tax liabilities |
|
|
2,183 |
|
|
|
2,183 |
|
Non-current operating lease liabilities |
|
|
376 |
|
|
|
640 |
|
Warrant liabilities |
|
|
21,948 |
|
|
|
44,865 |
|
Total liabilities |
|
|
38,803 |
|
|
|
59,265 |
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, 5,000,000 shares authorized at September 30, 2025 and December 31, 2024: |
|
|
|
|
|
|
Series X1 non-voting convertible preferred stock, $0.001 par value, 515,000 shares designated; 110,086 shares issued and outstanding at September 30, 2025 and December 31, 2024 |
|
|
53,543 |
|
|
|
53,543 |
|
Series X non-voting convertible preferred stock, $0.001 par value, 10,000 shares designated; 4,422 shares issued and outstanding at September 30, 2025 and December 31, 2024 |
|
|
2,151 |
|
|
|
2,151 |
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Common stock, $0.001 par value, 300,000,000 shares authorized at September 30, 2025 and 200,000,000 at December 31, 2024; 59,881,775 and 59,789,275 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively |
|
|
60 |
|
|
|
60 |
|
Additional paid-in capital |
|
|
426,047 |
|
|
|
417,946 |
|
Accumulated other comprehensive income |
|
|
9 |
|
|
|
26 |
|
Accumulated deficit |
|
|
(390,756 |
) |
|
|
(355,586 |
) |
Total stockholders’ equity |
|
|
35,360 |
|
|
|
62,446 |
|
Total liabilities, convertible preferred stock and stockholders’ equity |
|
$ |
129,857 |
|
|
$ |
177,405 |
|
ELEDON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months
Ended September 30, |
|
|
For the Nine Months
Ended September 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
14,969 |
|
|
$ |
16,520 |
|
|
$ |
48,776 |
|
|
$ |
34,036 |
|
General and administrative |
|
|
4,101 |
|
|
|
3,990 |
|
|
|
12,991 |
|
|
|
11,845 |
|
Total operating expenses |
|
|
19,070 |
|
|
|
20,510 |
|
|
|
61,767 |
|
|
|
45,881 |
|
Loss from operations |
|
|
(19,070 |
) |
|
|
(20,510 |
) |
|
|
(61,767 |
) |
|
|
(45,881 |
) |
Other income, net |
|
|
1,047 |
|
|
|
1,042 |
|
|
|
3,680 |
|
|
|
2,485 |
|
Change in fair value of warrant liabilities |
|
|
564 |
|
|
|
96,439 |
|
|
|
22,917 |
|
|
|
51,829 |
|
Net income (loss) |
|
$ |
(17,459 |
) |
|
$ |
76,971 |
|
|
$ |
(35,170 |
) |
|
$ |
8,433 |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on available-for-sale securities, net |
|
|
57 |
|
|
|
102 |
|
|
|
(17 |
) |
|
|
102 |
|
Comprehensive income (loss) |
|
$ |
(17,402 |
) |
|
$ |
77,073 |
|
|
$ |
(35,187 |
) |
|
$ |
8,535 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common shares - basic |
|
$ |
(16,130 |
) |
|
$ |
54,429 |
|
|
$ |
(32,492 |
) |
|
$ |
5,551 |
|
Basic net income (loss) per common share |
|
$ |
(0.21 |
) |
|
$ |
1.05 |
|
|
$ |
(0.42 |
) |
|
$ |
0.13 |
|
Weighted-average number of shares outstanding, basic |
|
|
77,156,068 |
|
|
|
51,945,920 |
|
|
|
77,146,407 |
|
|
|
41,443,049 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common shares - diluted |
|
$ |
(16,130 |
) |
|
$ |
(15,703 |
) |
|
$ |
(32,492 |
) |
|
$ |
(53,230 |
) |
Diluted net loss per common share (2024 As Restated) |
|
$ |
(0.21 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.42 |
) |
|
$ |
(1.23 |
) |
Weighted-average number of shares outstanding - diluted |
|
|
77,156,068 |
|
|
|
55,478,342 |
|
|
|
77,146,407 |
|
|
|
43,106,746 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Series X and Series X1 non-voting convertible preferred stock - basic |
|
$ |
(1,330 |
) |
|
$ |
6,666 |
|
|
$ |
(2,679 |
) |
|
$ |
852 |
|
Basic net income (loss) per Series X and Series X1 non-voting convertible preferred stock (2024 As Restated) |
|
$ |
(11.61 |
) |
|
$ |
58.21 |
|
|
$ |
(23.40 |
) |
|
$ |
7.44 |
|
Weighted-average shares outstanding of Series X and Series X1 non-voting convertible preferred stock, basic |
|
|
114,508 |
|
|
|
114,508 |
|
|
|
114,508 |
|
|
|
114,508 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Series X and Series X1 non-voting convertible preferred stock - diluted |
|
$ |
(1,330 |
) |
|
$ |
(1,801 |
) |
|
$ |
(2,679 |
) |
|
$ |
(7,856 |
) |
Diluted net loss per Series X and Series X1 non-voting convertible preferred stock (2024 As Restated) |
|
$ |
(11.61 |
) |
|
$ |
(15.73 |
) |
|
$ |
(23.40 |
) |
|
$ |
(68.60 |
) |
Weighted-average shares outstanding of Series X and Series X1 non-voting convertible preferred stock, diluted |
|
|
114,508 |
|
|
|
114,508 |
|
|
|
114,508 |
|
|
|
114,508 |
|
